IDEAYA Biosciences/IDYA

$46.18

0.65%
-
1D1W1MYTD1YMAX

About IDEAYA Biosciences

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

Ticker

IDYA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Yujiro Hata

Employees

124

Headquarters

South san francisco, United States

IDYA Metrics

BasicAdvanced
$3.42B
Market cap
-
P/E ratio
-$1.96
EPS
0.81
Beta
-
Dividend rate

What the Analysts think about IDYA

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 9 analysts.
9.48% upside
High $55.00
Low $40.00
$46.18
Current price
$50.56
Average price target

IDYA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-869.23% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.9M
-51.25%
Net income
$-33.9M
23.72%
Profit margin
-869.23%
153.79%

IDYA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.49
-$0.50
-$0.46
-
Expected
-$0.55
-$0.56
-$0.49
-$0.52
Surprise
-10.76%
-10.16%
-7%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell IDEAYA Biosciences stock

Buy or sell IDEAYA Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing